DeepMed Research

Universität Münster

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

Phase 2

Recruiting

Conditions: B-cell Lymphoma Refractory
B-cell Lymphoma Recurrent

Interventions: Procedure: Leukapheresis
Drug: Bridging Therapy
Drug: Lymphodepletion
Genetic: Axicabtagene Ciloleucel

First Posted Date: 2025-04-04

Last Posted Date: 2025-04-04

Lead Sponsor: Universität Münster

Target Recruit Count: 40

Registration Number: NCT06912529

Locations: 🇩🇪
Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie Universitätsklinikum Münster, Münster, Germany

ESGE-Quality Improvement in Endoscopy: ERCP

Conditions: Post-ERCP Acute Pancreatitis

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: Universität Münster

Target Recruit Count: 1254

Registration Number: NCT06727851

Locations: 🇩🇪
University of Muenster, Josephs Hospital Warendorf, Academic Teaching Hospital, Warendorf, Germany

Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)

Phase 1

Recruiting

Conditions: Anaplastic Astrocytoma (AA)
Anaplastic Oligodendroglioma (AO)
Glioblastoma (GBM)

Interventions: Drug: 5-Aminolevulinic acid Hydrochloride (Gliolan®)
Device: CV01

First Posted Date: 2024-10-30

Last Posted Date: 2025-03-10

Lead Sponsor: Universität Münster

Target Recruit Count: 14

Registration Number: NCT06665724

Locations: 🇩🇪
Department of Neurosurgery, University Hospital Münster, Münster, Germany

Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients

Recruiting

Conditions: Organ Transplantation

First Posted Date: 2024-10-22

Last Posted Date: 2024-11-08

Lead Sponsor: Universität Münster

Target Recruit Count: 30

Registration Number: NCT06652919

Locations: 🇩🇪
Institute of Pharmaceutical and Medicinal Chemistry, Clinical Pharmacy, University of Münster, Münster, Nordrhein-Westfalen, Germany

Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II

Phase 3

Not yet recruiting

Conditions: Cardiac Surgery
Vasoplegia

Interventions: Drug: Angiotensin II
Drug: Noradrenalin

First Posted Date: 2024-09-26

Last Posted Date: 2024-09-26

Lead Sponsor: Universität Münster

Target Recruit Count: 1022

Registration Number: NCT06615102

Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer

Phase 2

Not yet recruiting

Conditions: Carcinoma, Intraductal, Noninfiltrating

Interventions: Drug: [68Ga]Ga-FAPI-46

First Posted Date: 2024-08-06

Last Posted Date: 2024-08-06

Lead Sponsor: Universität Münster

Target Recruit Count: 30

Registration Number: NCT06540872

Locations: 🇩🇪
Department of Nuclear Medicine, University Hospital Essen, Essen, NRW, Germany
🇩🇪
Department of Nuclear Medicine, University Hospital Münster, Münster, NRW, Germany

Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury

Recruiting

Conditions: Acute Kidney Injury

Interventions: Procedure: Nephroprotective measures

First Posted Date: 2024-06-25

Last Posted Date: 2024-12-12

Lead Sponsor: Universität Münster

Target Recruit Count: 257

Registration Number: NCT06472999

Locations: 🇦🇹
Universitätsklinik Innsbruck, Innsbruck, Austria
🇳🇱
Radboud University medical cener, Nijmegen, Netherlands
🇩🇪
University Hospital Münster; Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Münster, Germany

Correlation of Cardiac Output Determined by Echocardiography and Indirect Calorimetry in Critically Ill Patients in Cardiogenic Shock on Extracorporeal Circulatory Life Support

Recruiting

Conditions: Cardiogenic Shock

First Posted Date: 2024-04-17

Last Posted Date: 2024-05-20

Lead Sponsor: Universität Münster

Target Recruit Count: 50

Registration Number: NCT06369818

Locations: 🇩🇪
University Hospital Münster, Münster, Germany

German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

Recruiting

Conditions: Fabry Disease

Interventions: Drug: Pegunigalsidase-alfa

First Posted Date: 2023-10-23

Last Posted Date: 2025-03-30

Lead Sponsor: Universität Münster

Target Recruit Count: 60

Registration Number: NCT06095713

Locations: 🇩🇪
Fabry disease center Berlin - Charité - Universitätsmedizin Berlin, Berlin, Germany
🇩🇪
Fabry disease center Hamburg, Universitätsklinikum Hamburg, Hamburg, Germany
🇩🇪
Fabry disease center Hannover, Universitätsklinikum Hannover, Hannover, Germany

and more 5 locations

Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI )

Not Applicable

Recruiting

Conditions: Acute Kidney Injury
Critical Illness

Interventions: Other: Effluent dose of CRRT

First Posted Date: 2023-09-01

Last Posted Date: 2024-11-27

Lead Sponsor: Universität Münster

Target Recruit Count: 165

Registration Number: NCT06021288

Locations: 🇩🇪
Universitätsklinikum Tübingen; Universitätsklinik für Anästhesiologie und Intensivmedizin, Tübingen, Germany
🇩🇪
University Hospital Münster, Münster, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy